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Abstract
Background: Coupling of alternative splicing with nonsense-mediated mRNA decay (NMD) may
regulate gene expression. We report here the identification of a nonsense alternative transcript of
the fumarylacetoacetate hydrolase (fah) gene, which produces a protein despite the fact that it is
subject to NMD.
Results: During the characterization of the effects of the W262X nonsense mutation on FAH
mRNA metabolism, two alternative transcripts (del100 and del231) of the fah gene were identified.
Del100 lacks exon 8 and as a consequence, the reading frame is shifted and a premature
termination codon appears at the 3'end of exon 10. Exons 8 and 9 are skipped in del231, without
any disruption of the reading frame. Specific amplification of these transcripts demonstrate that
they are produced through minor alternative splicing pathways, and that they are not caused by the
W262X mutation per se. As shown with an antiserum raised against the C-terminal part of the
putative DEL100 protein, the del100 transcript produces a protein, expressed at different levels in
various human tissues. Interestingly, the del100 transcript seems to be subjected to nonsense-
mediated mRNA decay, as its level was stabilized following a cycloheximide treatment.
Conclusions: The del100 and del231 transcripts arise due to minor alternative splicing pathways
and del100 is likely subjected to nonsense-mediated mRNA decay. However the remaining amount
of transcript seems sufficient to produce a protein in different human tissues. This suggests that
NMD has a broader role than simply eliminating aberrant transcripts and when coupled to
alternative splicing, may act to modulate gene expression, by allowing the production of low
amounts of protein.
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Background
Cells have evolved surveillance mechanisms to ensure the
fidelity of gene expression. One such mechanism, non-
sense-mediated mRNA decay (NMD), was discovered
about twenty years ago in yeast [1] and then described in
human inherited diseases caused by nonsense or
frameshift mutations [2-4], which introduce premature
termination codons (PTCs). Contrary to what would be
predicted based on the nature of the mutation (a prema-
ture translational arrest), the resulting nonsense mRNAs
rarely code for truncated protein products and are rather
rapidly degraded [5]. Hence, NMD was first envisaged as
a mean to protect cells against the effects of deleterious
truncated proteins, with potential dominant-negative
effects or a gain of function. Moreover, it seems that NMD
has not solely evolved under the pressure of nonsense
mRNAs originating from mutations but it also monitors
PTC-containing transcripts arising from abnormalities in
gene expression [6]. NMD plays a role in normal cellular
development as examplified by the production of func-
tional TcR and Ig genes. During lymphocyte maturation,
these genes are subjected to extensive rearrangements and
somatic mutation events. Approximately two-thirds of the
rearranged genes are not in the proper translational read-
ing frame and the resulting transcripts are down-regulated
by NMD, ensuring that only functional TcR and Ig genes
are expressed [7,8]. More recently, it was suggested that
NMD could play a role in the regulation of gene expres-
sion. This was first suspected following the identification
of unproductive splicing products of the SRp20 and
SRp30b proteins or the ribosomal proteins L3, L7a, L10a
and L12 in Caenorhabditis elegans [9,10]. The coupling of
alternative splicing, which generates transcripts contain-
ing PTCs and NMD, which degrades these transcripts, ena-
bles the negative regulation of gene expression [9,10].
This system, termed RUST (for Regulated Unproductive
Splicing and Translation, [11]) is also used in humans
[12-14]. It was suggested that alternative splicing leading
to NMD might prove to be a common mechanism of
autoregulation of many splicing factors [12,15,16]. For
example, the polypyrimidine tract binding protein (PTB),
which generally acts as a splicing repressor, downregulates
its own expression by repressing exon 11 inclusion in the
mature mRNA [12]. The resulting alternative PTB mRNA
lacking exon 11 contains a PTC and is subjected to NMD
[12]. This negative autoregulation prevents the accumula-
tion of PTB, and therefore the inappropriate processing of
its targets [12]. This coupling of alternative splicing and
NMD seems to be a rather common mechanism, as in sil-
ico analyses show that 35% of EST-suggested alternative
transcripts contain PTCs [17]. Alternative splicing is
thought to occur in 30–60% of human genes [18], and in
addition to expanding proteome diversity, it may play a
role in gene expression regulation by generating PTC-con-
taining alternative isoforms. Interestingly, 10 to 30% of
nonsense transcripts can escape NMD and are further
immune to degradation [19]. Whether such transcripts
code for proteins with a physiological function is
unknown.
Fumarylacetoacetate hydrolase (FAH, E.C. 3.7.1.2) is the
last enzyme of the tyrosine catabolic pathway. A defi-
ciency in FAH causes hereditary tyrosinemia type I (HTI;
OMIM 276700), the most severe disease of the pathway
[20]. This inherited metabolic disorder is characterized by
severe hepatic and renal dysfunctions often resulting in
death in the first years of life if untreated. HTI displays
phenotypic heterogeneity with both chronic and acute
forms [20,21]. The fah coding gene located on chromo-
some 15 in the q23-q25 region [22] spans over 35 kb and
contains 14 exons [23]. Forty-seven mutations have been
identified so far in the fah gene, including 7 nonsense
mutations [24-26]. While characterizing the effects of the
W262X nonsense mutation on FAH mRNA metabolism,
we identified two alternative transcripts, del100 and
del231 in a HTI patient homozygous for W262X. These
transcripts are found in normal cells and thus are not due
to the nonsense mutation per se. Interestingly, del100 has
skipped exon 8 and as a consequence, the reading frame is
shifted, with the appearance of several new PTCs. This
transcript is therefore likely subjected to NMD, as sug-
gested by a block of translation by cycloheximide. How-
ever, the amount of nonsense transcript which escapes
NMD seems to be sufficient to produce a protein of 31-
kDa, detected in several human tissues. This report sug-
gests that NMD may allow for the production of low
amounts of protein.
Results
Identification of two alternative transcripts of the fah gene
The W262X mutation is a G->A transversion located in
exon 9 of the fah gene at nucleotide position 786 and is
frequent in the Finnish population [27]. No protein was
detected in the liver or the fibroblasts of homozygous
patients [28]. Consistent with this type of mutation, we
demonstrated that W262X mRNAs are degraded by NMD
in the cytoplasm [29]. While studying the decay of W262X
nonsense FAH transcripts in lymphoblastoid cell lines, we
repeatedly observed two additional RT-PCR products in
homozygous W262X/W262X cells (Figure 1A). Purifica-
tion and sequence analysis of these two products revealed
that they were alternative transcripts of the fah gene. The
first one, del100, lacks exon 8 (Figure 1A) and the second
one, del231, which is less abundant, lacks both exons 8
and 9 (Figure 1A). In del100, the skipping of exon 8 from
the mature transcript causes a shift in the reading frame
and as a consequence, several new PTCs appear, the first
one being located at the 3' end of exon 10, at the new
amino acid position 270 (Figure 1A). The G786A muta-
tion does not code for a stop codon in del100 but causesBMC Molecular Biology 2005, 6:1 http://www.biomedcentral.com/1471-2199/6/1
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Del100 and del231 result from minor alternative splicing pathways and not from the presence of the W262X mutation Figure 1
Del100 and del231 result from minor alternative splicing pathways and not from the presence of the W262X 
mutation. Total RNA extracted from different normal cell lines or cells of HTI patients was subjected to RT-PCR. Controls 
for FAH, del100 and del231 are displayed on the left to show that the PCR reactions are in the linear range. (A) FAH amplifica-
tion from exons 6 to 14 in the lymphoblastoid cell lines. The two additional products (del100 and del231) seen in the 
homozygous cell line (W262X/W262X) are depicted below the gels. Exons are represented by boxes and introns by lines. 
Del100 has skipped exon 8 and as a consequence, the reading frame is shifted (W262X becomes G229E). A first PTC is located 
at the 3'end of exon 10 (270X). Del231 has skipped both exons 8 and 9, but without any change in the reading frame. (B) Prim-
ers designed to specifically amplify del100 and del231 span exon 7 to 9 or exon 7 to 10 junctions respectively (depicted in 
blue). Full-length, del100 or del231 cDNAs were cloned in pRC/CMV and were amplified to verify primer specificity to each 
alternative transcript. Both transcripts are present in normal cells (wild-type lymphoblasts or fibroblasts and HeLa cells) and 
human liver. Del100 is amplified in HTI cells with a splice mutation in exon 12 (IVS12/ IVS12) or two nonsense mutations in 
exon 13 (E357X/E364X). FAH was also amplified as a control in the different human cell lines.BMC Molecular Biology 2005, 6:1 http://www.biomedcentral.com/1471-2199/6/1
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the replacement of a glycine by a glutamate residue (Fig-
ure 1A). Del231 does not show further disruption of the
open reading frame downstream of the deletion and is
predicted to code for a shorter FAH-like protein (about
34-kDa) missing the region encoded by exons 8 and 9
(Figure 1A).
Del100 and del231 were first identified in the liver of a
patient harboring another mutation (Q279R), which
weakens the donor splice site of exon 9 [30]. Because the
W262X mutation is located in the same exon and that in
some cases a nonsense codon can affect splicing [31], we
wondered whether these two transcripts were due to an
effect of the W262X mutation on a cis-acting splicing ele-
ment in exon 9. To test this hypothesis, RT-PCRs were per-
formed using primers spanning the exon7-exon9 junction
or the exon7-exon10 junction to specifically amplify
del100 and del231 respectively. As shown in Figure 1B,
both del100 and del231 transcripts were detected by this
method, in homozygous mutant cells (W262X/W262X;
Figure 1B, middle panel), as well as in normal cells (wt/
wt; Figure 1B, middle panel). The identity of these ampli-
fication products was verified by sequencing (data not
shown). A similar result was found in various human cell
lines (Figure 1B, right panel). Indeed, del100 and del231
were amplified in fibroblasts, HeLa cells (Figure 1B, right
panel) and in human liver (Figure 1B, right panel), the tis-
sue where FAH is the most expressed [32]. Moreover,
del100 was amplified in two HTI cell lines (Figure 1B),
which harbor either a splice mutation in intron 12
(IVS12/IVS12; [33]) or two nonsense mutations in exon
13 (E357X/E364X; [33]). Del231 was not detected in
these two cell lines as expected, since these mutations
introduce PTCs either following exon 12 skipping (IVS12/
IVS12) or due to the two nonsense mutations themselves
(E357X and E364X), that likely target the nonsense tran-
scripts to the NMD pathway.
Altogether, these data strongly argue in favor of del100
and del231 being minor alternative transcripts of the fah
gene, rather than resulting from the presence of the
W262X mutation.
The del100 transcript is translated into a protein
The identification of two minor alternative transcripts of
the fah  gene raised the question whether they resulted
from errors of the splicing apparatus and were unproduc-
tive alternative transcripts or whether they could produce
protein products with potential physiological roles. There
is presently no reported indication for the existence of
additional FAH isoforms. The DEL231 open reading
frame is identical to FAH, except for the missing region
encoded by the skipped exons 8 and 9 and corresponding
to amino acids 203 to 280 (Figure 2A). The open reading
frame of the del100 transcript is identical to FAH and
del231 from the ATG start codon to amino acid 202.
However, the last 67 amino acids of the putative DEL100
protein encoded by exons 9 and 10 are completely differ-
ent, due to the shift in the reading frame following exon 8
skipping (Figure 2A). To find out if del100 was translated
into a protein, we raised an antiserum against the last 67
amino acids of the putative DEL100 protein and used it to
search for the presence of this protein in different adult
human tissues. These tissues were obtained after an
autopsy and only one sample per tissue was tested, due to
the difficulty to obtain them. As shown in Figure 2B (mid-
dle panel), a cross-reacting band was present in heart,
liver, kidney, spleen, suprarenals and bladder. The
DEL100 protein has an apparent molecular weight of 31-
kDa, consistent with the value of 29.7-kDa calculated
from its sequence. Interestingly, the expression level of the
DEL100 protein varied between the different tissues and it
differed from that of FAH (Figure 2B, top panel). For
example, FAH was barely detected in the spleen, whereas
the expression level of the DEL100 protein was the highest
in this tissue (Figure 2B). A monoclonal antibody directed
against the N-terminal part of the FAH protein was used
to detect both FAH and DEL100 in the tissues where FAH
is the less expressed (Figure 2C). DEL100 was barely
detected in the spleen, suggesting that the protein is syn-
thezised in very low amounts.
The specificity of the signal was verified by adsorbing the
antiserum on the purified C-terminus of DEL100, used for
the mouse immunization. As shown in Figure 3A (top
panel), the affinity-purified antiserum still recognized the
31-kDa protein, whereas the non-adsorbed fraction did
not show any cross-reactivity (Figure 3A, bottom panel).
The protein of low molecular weight, which is recognized
by the non-adsorbed antiserum in the spleen, is unspecific
background (Figure 2B, middle panel and Figure 3A, bot-
tom panel; indicated by a star). A DEL100 protein with
the Myc tag was synthesized in an in vitro transcription-
translation assay and immunoprecipitated using an anti-
Myc antibody. The anti-DEL100 antiserum recognizes the
immunoprecipitated DEL100-Myc protein, further dem-
onstrating its specificity (Figure 3B). Altogether these
results suggest that the del100 alternative transcript is
translated into a protein of 31-kDa whose expression in
different tissues differs from that of FAH.
The del100 transcript seems to be subjected to NMD
The skipping of exon 8 in del100 causes a change in the
reading frame and as a consequence, several new stop
codons appear (different from the W262X mutation). To
verify if the nonsense del100 transcript was subjected to
NMD, lymphoblastoid cells were treated with cyclohex-
imide (Figure 4) an inhibitor of translation. Stabilization
of nonsense transcripts following such a treatment sug-
gests that they are degraded through the NMD pathwayBMC Molecular Biology 2005, 6:1 http://www.biomedcentral.com/1471-2199/6/1
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Del100 transcript encodes for a protein expressed in various tissues Figure 2
Del100 transcript encodes for a protein expressed in various tissues. (A) Schematic representation of the putative 
DEL100 and DEL231 proteins. FAH and DEL231 proteins are identical, except for the region encoded by exons 8 and 9, which 
is missing in DEL231. DEL100, due to the skipping of exon 8 and the resulting change in the coding frame, differs from FAH at 
its C-terminal end. The black bar below the DEL100 protein represents the region used to raise the antiserum. (B) 30 µg pro-
teins of a 10% (w/v) tissue homogenate were separated on a 15% SDS-polyacrylamide gel. Proteins were transferred to a nitro-
cellulose membrane and blotted using a rabbit anti-FAH (top panel; dilution 1:25,000) or a mouse anti-DEL100 antiserum 
(middle panel; dilution 1:1,000). A band with an apparent molecular weight of 31-kDa is detected by the anti-DEL100 antiserum 
in all tissues tested. The star indicates non-specific signal. The membrane was blotted against β-actin to control for protein 
loading. (C) The 31-kDa band (indicated by a red arrow) was detected in spleen using a monoclonal antibody directed against 
the N-terminal part of the FAH (green arrow).BMC Molecular Biology 2005, 6:1 http://www.biomedcentral.com/1471-2199/6/1
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Specificity of the anti-DEL100 antiserum Figure 3
Specificity of the anti-DEL100 antiserum. (A) The mouse antiserum was affinity purified on the recombinant C-terminal 
of DEL100 and used to probe the same membrane as in Figure 2B. The adsorbed fraction (top panel), specific of the C-terminal 
of DEL100, still recognizes the 31-kDa protein. The non-adsorbed fraction (bottom panel) shows no cross-reactivity to the 
protein. The star indicates a non-specific signal. (B) The DEL100-Myc protein was synthesized in a rabbit reticulocyte lysate and 
labeled with 35S (translation panel). The tagged protein is indicated by an arrow. The band below is the protein synthesized 
without the Myc tag. The anti-Myc was immobilized on protein A-sepharose and incubated with in vitro translated DEL100-Myc. 
Effectiveness of the immunoprecipitation was verified by blotting using the anti-Myc (1/2,000) antibody. The anti-DEL100 
antiserum (1/1,000) recognizes the in vitro translated protein in the input (10% of the reaction) and the immunoprecipitate (IP, 
indicated by an arrow).BMC Molecular Biology 2005, 6:1 http://www.biomedcentral.com/1471-2199/6/1
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Del100 is subjected to NMD Figure 4
Del100 is subjected to NMD. Control cells (wt/wt) and the homozygous cell line from the Finnish patient (W262X/
W262X) were treated with 100 µg/ml cycloheximide (CHX) for 3 hours. Total RNA was extracted and subjected to RT-PCR. 
RAR serves as a control for RNA quantity in each sample. Control amplifications (showing an increasing number of cycles) for 
del100, del231 and RAR are displayed on the left to show that, with the conditions used, each PCR reaction is in the exponen-
tial phase. (A) [α33P]-dATP was incorporated during the PCR reaction and the products loaded on a 6% acrylamide gel. The gel 
was used to directly expose an X-ray film and the signal was quantified using the NIH Image 1.2 software. FAH was amplified 
from exons 6 to 14 (the del100 transcript which is detected using these primers is indicated by a star). Del100 and del231 
were amplified using the specific primers RT84 and RT85. (B) Quantification of the amount of del100 mRNA in 3 different 
experiments, normalized to RAR levels. The error bars represent standard deviations. Del100 is stabilized between 4- to 7-fold 
in homozygous cells (W262X/W262X) and normal cells (wt/wt) following the cycloheximide treatment (yellow bars: - 
cycloheximide; purple bars: + cycloheximide). (C) del231 is relatively unaffected by translation inhibition.BMC Molecular Biology 2005, 6:1 http://www.biomedcentral.com/1471-2199/6/1
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[34]. The effectiveness of the treatment was previously ver-
ified on the full-length W262X containing transcript [29]
and an example is given in Figure 4A (upper panel). The
full-length transcript was up-regulated in the homozygous
cell line (Figure 4A; W262X/W262X) but remains unaf-
fected in wild-type cells (Figure 4A; wt/wt). The same
treatment was used to determine the fate of the del100
transcript (Figure 4A and 4B). A stabilization of this alter-
native transcript was observed when the FAH transcripts
were amplified from exons 6 to 14 in wild-type and
homozygous cells (indicated by a star in Figure 4A). The
same result was obtained using a specific amplification of
the del100 transcript (Figure 4A, second panel and Figure
4B). The amount of del100 following cycloheximide treat-
ment increased about 5-fold the level observed in
untreated cells (Figure 4B). These results suggested that
del100 is indeed subjected to NMD in homozygous cells
and in normal cells as well. In contrast del231, which does
not contain any PTC as a result of the skipping of both
exons 8 and 9, seemed relatively unaffected by the
cycloheximide treatment as expected (Figure 4C) and
does not seem to be subjected to NMD. This result con-
firmed those obtained in E357X/E364X or IVS12/IVS12
HTI fibroblasts (Figure 1B), where del231 was undetecta-
ble probably because of the introduction of PTCs in these
transcripts and their targeting to the NMD pathway.
Discussion
Del100 and del231 were originally identified while stud-
ying the impact of NMD on hereditary tyrosinemia type I.
During the characterization of the effects of the W262X
mutation on FAH mRNA metabolism [29], we detected
two minor alternative transcripts. If due to the W262X
mutation, they should only be produced when the non-
sense mutation is present, i.e. in heterozygous (W262X/
wt) and homozygous (W262X/W262X) cell lines. How-
ever, by using specific primers for each transcript, we
found that both del100 and del231 are produced in nor-
mal lymphoblastoid cells (Figure 1B) and in normal
human liver. Del100 was also present in two different HTI
cell lines harboring different nonsense mutations
(E357X/E364X) or a splice mutation (IVS12+5g->a) in
exon 13 or intron 12 respectively. These data argue in
favor of del100 and del231 resulting from alternative
splicing pathways rather than from a W262X-associated
altered splicing mechanism. We suggest that both tran-
scripts result from a weak definition of exon 8 (Figure 5).
Indeed, exon 8 is subjected to many alterations as a result
of splice mutations in the region encompassing exons 6 to
9. For example, due to a splice mutation in intron 6 (IVS6-
1g->t; [30,35]), a cryptic acceptor site in exon 8 is acti-
vated or exon 8 is skipped [30,35]. Del100 and del231
were also identified in the case of the Q279R mutation, a
splicing mutation that weakens the donor splice site of
exon 9 [30]. Figure 5 presents with a model that could
explain these observations: we suggest that in the major
splicing pathway, intron 8 is removed before introns 7
and 9, leading to a splice intermediate that contains the
merged exons 8 and 9. Both exons are subsequently
defined as a single exon. The order of intron removal is an
important determinant of the outcome of splice-site
mutations and could explain some unusual alterations,
like the skipping of contiguous exons, as strongly sug-
gested by studies of the COL1A1 and COL5A1 splice
mutations [36,37]. Altogether, these data suggest that at
least del231 may arise through a minor splicing pathway
due to an error-prone splicing apparatus because of the
weak definition of exon 8 and the order of intron removal.
Del100 could originate from a second minor splicing
pathway, in which exon 8 is skipped alone because of its
weak definition (Figure 5).
Del100 and del231 are thus the first cases of alternative
splicing for the fah  gene. However, it remained to see
whether they were unproductive splice isoforms or
whether they could code for protein isoforms. The del231
transcript retains an unchanged open reading frame when
compared to FAH. The putative DEL231 protein would be
similar to FAH except for the lower molecular weight
(about 35-kDa), due to the missing region encoded by
exons 8 and 9. We have been unable to detect a protein
species of the size that could correspond to DEL231 using
an antibody against full-length FAH. Whether this reflects
the absence of such a protein or its presence in a very low
amount undetectable with the presently available anti-
bodies remains unknown. The latter explanation seems
plausible since the del231 transcript, although not sub-
jected to NMD, is much less abundant that the full-length
FAH transcript or del100, as it is barely detected in W262X
cells with the RT76 and RT025 primers (Figure 1) and the
number of PCR cycles needed for its visualization is
higher than for del100 when using the specific primers.
The structure of the putative DEL100 protein in the N-ter-
minal part is identical to that of FAH. But due to exon 8
skipping, the reading frame is very different in the last 67
amino acids. DEL100, a 31-kDa protein, was detected in
different human tissues using an antiserum raised against
the specific C-terminal part of the putative protein. The
antiserum is specific for the DEL100 protein and does not
cross-react with FAH. In addition, the cross-reacting 31-
kDa band was lost after adsorbing the antiserum against
the purified peptide used for the immunization and the
antiserum recognizes an in vitro translated DEL100-Myc
protein, demonstrating its specificity. Thus the del100
transcript seems to direct the synthesis of a protein. This
result is surprising because this transcript contains PTCs
and seems to be subjected to NMD, as shown by a block
of translation following a cycloheximide treatment. Inter-
estingly, FAH and DEL100 have converse expression pat-BMC Molecular Biology 2005, 6:1 http://www.biomedcentral.com/1471-2199/6/1
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terns in the human tissues examined. This suggests a post-
transcriptional regulation of the expression of the two
proteins, since the two transcripts originate from the same
pre-mRNA. Alternative splicing, a highly regulated
process, which can be developmental-stage or cell-spe-
cific, could be responsible for this difference of expres-
sion. For example, exon 8 may be more prone to skipping
in the spleen given the concentration of specific trans-act-
ing splicing regulators. This could be a way to downregu-
late the level of FAH transcript, by producing an
alternative transcript, which is further eliminated by
NMD. Indeed recent in silico analyses and observations on
splicing factors have suggested that NMD, when coupled
to alternative splicing, could regulate gene expression [10-
12,17]. Del100 could be another example of such a cou-
pling of alternative splicing and NMD. In such a case,
DEL100 would not be expected to play any function in the
cell.
Very low levels of proteins can sometimes have enormous
effects. Interestingly, 10–30% of nonsense transcripts
escape NMD and when associated with polysomes are sta-
Suspected splicing pathways of the region encompassing exons 6 to 10 Figure 5
Suspected splicing pathways of the region encompassing exons 6 to 10. Schematic representation of exon 8 and its 
splice sites is given on the top of the figure. The effectiveness of the donor and acceptor splice sites were determined using the 
webgene program http://itba.cnr.it/webgene/ and is indicated above the sequence. A cryptic acceptor splice site is used in the 
case of the IVS6-1g->t mutation (described in [35]). Exons are represented by boxes and introns by lines. The thick arrow is 
the major splicing pathway, whereas thin arrows are minor alternative splicing pathways. We suggest that del231 could be 
explained by the fact that intron 8 is spliced out before introns 7 and 9, leading to an intermediate in which exons 8 and 9 are 
defined together. Because of exon 8 weak definition, a minority of transcripts eliminates both exons 8 and 9. Del100 could be 
produced by another minor splicing pathway, in which exon 8 is skipped alone.BMC Molecular Biology 2005, 6:1 http://www.biomedcentral.com/1471-2199/6/1
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ble [19]. Is the coupling of alternative splicing with NMD
in order to degrade the unproductive isoform the only
option? An alternative, as proposed by Neu-Yilik et al.
[38], may be that NMD could function in quantitatively
controlling the expression of low amounts of protein. In
this view, the PTC-containing del100 transcript may
produce a protein with a physiological, although still
unknown, function in the cell. The FAH structure contains
a C-terminal part of 300 residues, which presents a novel
arrangement of β-strands and plays a functional role in
Ca2+ binding, dimerization and catalysis of its substrate,
fumarylacetoacetate [39]. Many of the residues encoded
by exon 8 are part of the β-strands and residue 233 serves
to bind the Ca2+ [39]. The DEL100 protein, which lacks
these residues, is thus very unlikely to function in catalyz-
ing the hydrolytic cleavage of carbon-carbon bonds.
While the function of DEL100 is unknown at this time, it
may have a function in tyrosinemia. Indeed, not all muta-
tions affecting the fah  gene will similarly affect the
DEL100 protein. For example, mutations affecting exons
downstream of exon 10 will affect FAH production but
not that of the DEL100 protein. This might be reflected in
the phenotypic heterogeneity observed in HTI patients
[21]. Preliminary computer analyses of DEL100 motifs
using Proscan at PBIL suggest that it contains a putative
DNA-binding motif (RVFLQNLLSvSQARLR with 89%
similarity found to the consensus sequence). Whether
DEL100 can function as a regulating factor remains
unknown.
Conclusions
NMD was first envisaged as a mechanism to prevent the
accumulation of faulty transcripts, arising from mutations
or processing abnormalities. Recent in vivo observations
and in silico analyses have suggested a new role of NMD in
gene expression regulation, when coupled to alternative
splicing. We report here the identification of an alterna-
tive nonsense transcript of the fah gene, which despite
being subjected to NMD, produces a protein in different
human tissues. This provides an interesting starting point
for the analysis of the role of NMD in the regulated pro-
ductive splicing and translation.
Methods
Cell culture
The lymphoblastoid cell lines were established from lym-
phocytes of a HTI patient and his parents as described in
Tremblay and Khandjian [40]. Cells were maintained in
RPMI-1640 supplemented with 15% fetal bovine serum.
The other human cell lines, HeLa (cervix) and normal
fibroblasts, were cultured in DMEM 10%. Fibroblasts of
other HTI patients (WG1647, mutation IVS12/IVS12; and
WG1922, mutation E357X/E364X [33]) obtained from
the Montreal Children's Hospital (C.R. Scriver) were
maintained in DMEM 10% FBS. In translation inhibition
experiments, lymphoblastoid cells were treated with 100
µg/ml cycloheximide 3 hours prior to RNA extraction (see
below).
RT-PCR analysis
Total RNA was extracted from 5·106 cells with Trizol rea-
gent (Gibco-BRL). RNA from human normal liver was
extracted using the RNAqueous kit (Ambion). 1 µg RNA
was reverse transcribed using an oligo(dT) and Stratascript
(Stratagene). FAH cDNA was amplified from exons 6 to
14 using the following primers: RT76 (5'-CGT GCC TCC
TCT GTC GTG-3') and RT025 (5'-GGG AAT TCT GTC ACT
GAA TGG CGG AC-3'). Sense primers were designed to
specifically amplify del100 and del231. RT84 (5'-TGG
AGC TGG AAA TGC ACG-3') spans the exon 7 to exon 9
junction, whereas RT85 (5'-TGG AGC TGG AAA TGG
ACC-3') spans the exon 7 to exon 10 junction. Amplifica-
tion of the alternative transcripts with RT84 or RT85 was
performed using HotStart (Qiagen) and PCR conditions
were optimized in order to minimize nonspecific hybrid-
ization of the primers. Moreover, for each amplification
(the FAH transcripts and RAR), the kinetic of the reactions
were performed and the number of cycles used for each
PCR was in the exponential phase.
Analysis of the cycloheximide treatment was done as pre-
viously described [29].
Production of an antiserum against the DEL100 protein
An antiserum against the C-terminal part of the DEL100
protein was raised in mouse. The antigen is the C-terminal
part (the last 67 amino acids) of the DEL100 protein and
is different from FAH or the DEL231 protein. FAH cDNA
was amplified from exon 9 to exon 14 using the primers
hFAHsstermdel100 (5'-CGG GAT CCC TGC AGC ACG
AGA CAT TCA GAA GTG G-3') and RT025 with Expand
High Fidelity. The PCR product was inserted into pET30a
(Novagen) at the BamHI and EcoRI sites, in order to
express the reading frame of the C-terminal part of the
DEL100 protein. The His-Tag fusion protein used for
immunization was purified by affinity chromatography
on a Ni-NTA column (Qiagen) in denaturing conditions
with 6 M urea.
Preparation of the anti-hFAH monoclonal antibody
The anti-hFAH monoclonal antibody was raised against
the N-terminus of the protein. The 161 residue peptide
was obtained by cutting the pET30a-FAH vector [41] with
the NcoI and XhoI restriction enzymes (New England
Biolabs), overhangs were then filled using T4 DNA
polymerase (New England Biolabs) and the vector was
ligated with the T4 DNA ligase (New England Biolabs).
The peptide was expressed in the GJ1158 strain of
Escherichia coli as previously described [41] and purified
by affinity chromatography on a Ni-NTA column underBMC Molecular Biology 2005, 6:1 http://www.biomedcentral.com/1471-2199/6/1
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denaturing conditions (6 M urea). The purified peptide
was injected into BALB/c mice and hybridomas were pre-
pared according to the procedures described in [42].
Western blot analysis
Cells were harvested and lysed in 1 × SDS sample buffer
(62.5 mM Tris-Hcl, pH 6.8, 2% SDS, 2.5% 2-β mercap-
toethanol, 75 mM DTT, 10% glycerol and 0.005%
Bromophenol blue). Human tissues obtained at autopsy
and stored at -70°C until used [32] were homogenized in
10% (w/v) 0.01 M K-phosphate buffer (pH 7.3) and cen-
trifuged for 20 min at 15,000 g. The supernatant was used
for immunoblot assay. Samples were electrophoresed on
SDS-15% polyacrylamide gels and proteins transferred to
a nitrocellulose membrane. Antiserum against the
DEL100 protein was used at a dilution of 1:20,000 against
purified proteins or 1:1,000 against human tissues. FAH
was detected using the polyclonal antibody #488
(1:25,000) as described previously [32] or using a mono-
clonal antibody directed against the N-terminal part of the
FAH protein (dilution 1/500). Protein loading was veri-
fied by using a monoclonal antibody against β-actin (dilu-
tion 1/400; Neomarker).
Tests of the specificity of the anti-DEL100 antiserum
In some experiments, the mouse antiserum against the
DEL100 protein was adsorbed on the recombinant His-
tag C-terminal protein blotted on nitrocellulose. After an
overnight incubation at 4°C, the non-adsorbed fraction
was removed and conserved for further characterization.
The adsorbed antibody fraction (affinity purified) was
eluted using 1 ml of glycine-HCl 0.1 M, pH 2.8 and the
pH immediately neutralized by adding 100 µl of 1 M
K2HPO4, pH 8.2.
The del100 cDNA was obtained by RT-PCR on total RNA
extracted from W262X/W262X cells using ND1 (5' CCC
AAG CTT CAG CAT GTC CTT CAT CCC GGT GG 3') and
ND2 (5' TGC TCT AGA TTT ATT TGT CAC TGA ATG GCG
G 3'). The amplification products were cloned into pDrive
(Qiagen) and different clones were sequenced. One clone
containing the del100 cDNA was used for further cloning.
It was amplified using 5'del100-Eco (5' GGA ATT CCA
GCA TGT CCT TCA TCC 3') and ND2. The amplified frag-
ment was digested with EcoRI and XbaI and ligated into
EcoRI-XbaI-digested pcDNA3-myc RANGAP, replacing
the insert coding for RANGAP. pcDNA3-mycRANGAP
was kindly provided by Dr M. J. Matunis (Johns Hopkins
University, Baltimore, MD) The construct was used for
coupled in vitro transcription-translation using the TNT
coupled reticulocyte lysate system (Promega) according to
the manufacturer's recommendations. 25 µl of the reac-
tion were used for immunoprecipitation using the anti-
Myc antibody as follows: the anti-Myc (1/100) was incu-
bated 1 hour with protein A-sepharose beads (Sigma). The
antibody was next immobilized on the beads using 20
mM dimethyl pimedilate (Sigma) in 0.2 M borate sodium
(pH 9.0) for 30 min at room temperature. The reaction
was stopped by washing the beads twice in 0.2 M eth-
anolamine and incubation in this solution for 2 hours at
room temperature. The antigen (25 µl of the in vitro trans-
lated DEL100-Myc protein) was incubated with the beads
for two hours at 4°C in a dilution buffer containing 10
mM Tris-HCl pH 8.0, 1 mM EDTA and 10% glycerol. The
immunoprecipitated protein was eluted by adding 25 µl
of SDS loading buffer (62.5 mM Tris-HCl, pH 6.8; 2%
SDS; 2.5% β-mercaptoethanol; 75 mM DTT; 10% glycerol
and 0.01% bromophenol blue). Samples were electro-
phoresed on SDS-15% polyacrylamide gels and proteins
transferred to a nitrocellulose membrane. The anti-Myc
was used at a dilution of 1/2,000 and the anti-DEL100
antiserum at a dilution of 1/1,000.
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